Cargando…
Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States
PURPOSE: To estimate the cost-effectiveness of Nefecon in addition to the best supportive care (BSC) vs BSC in a hypothetical cohort of commercially insured adult patients with primary immunoglobulin A nephropathy (IgAN) from a United States (US) societal perspective. METHODS: A lifetime horizon, se...
Autores principales: | Ramjee, Lauren, Vurgun, Nesrin, Ngai, Christopher, Patel, Mit, Tremblay, Gabriel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067365/ https://www.ncbi.nlm.nih.gov/pubmed/37020570 http://dx.doi.org/10.2147/CEOR.S389456 |
Ejemplares similares
-
Microbiota and Metabolome Associated with Immunoglobulin A Nephropathy (IgAN)
por: De Angelis, Maria, et al.
Publicado: (2014) -
The molecular mechanisms of inflammation and scarring in the kidneys of immunoglobulin A nephropathy: Gene involvement in the mechanisms of inflammation and scarring in kidney biopsy of IgAN patients
por: Schena, Francesco Paolo, et al.
Publicado: (2021) -
IgAN Genetic Risk Score in the Clinical Setting
por: Schena, Francesco Paolo, et al.
Publicado: (2020) -
New directions in the pathogenesis of primary erythrocytosis in IgAN
por: Schena, Francesco Paolo, et al.
Publicado: (2022) -
Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study
por: Rizk, Dana V., et al.
Publicado: (2023)